Tosolini, Marie; Centre de Recherches en Cancerologie de Toulouse, Inserm, CNRS, Universite de Toulouse, Toulouse, France
Villard, Amélie ; Centre de Recherches en Cancerologie de Toulouse, Inserm, CNRS, Universite de Toulouse, Toulouse, France
Cayron, Coralie; Centre de Recherches en Cancerologie de Toulouse, Inserm, CNRS, Universite de Toulouse, Toulouse, France
Baer, Romain; Centre de Recherches en Cancerologie de Toulouse, Inserm, CNRS, Universite de Toulouse, Toulouse, France
Bertrand-Michel; Lipidomics, I2MC, Inserm, Toulouse, France
Pagan, Delphine; Centre de Recherches en Cancerologie de Toulouse, Inserm, CNRS, Universite de Toulouse, Toulouse, France
Ferreira Da Mota, Dina; Centre de Recherches en Cancerologie de Toulouse, Inserm, CNRS, Universite de Toulouse, Toulouse, France
Yan, Hongkai; Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
Falcomata, Chiara; Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
Muscari, Fabrice; Centre de Recherches en Cancerologie de Toulouse, Inserm, CNRS, Universite de Toulouse, Toulouse, France
Bournet, Barbara; Centre de Recherches en Cancerologie de Toulouse, Inserm, CNRS, Universite de Toulouse, Toulouse, France
Delord, Jean-Pierre; Centre de Recherches en Cancerologie de Toulouse, Inserm, CNRS, Universite de Toulouse, Toulouse, France
Aksoy, Ezra; Centre for Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London, UK
Abdallah R, Taly V, Zhao S, Pietrasz D, Bachet J-B, Basile D, Mas L, Zaanan A, Laurent-Puig P, Taieb J (2020) Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: a systematic review. Cancer Treat Rev 87: 102028
Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P, Hauser K, Hahnfeldt P, Hlatky L, Debus J et al (2007) Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA 104: 12890–12895
Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, Cornish TC, Iacobuzio-Donahue CA, Vonderheide RH, Stanger BZ (2016) Metastatic progression is associated with dynamic changes in the local microenvironment. Nat Commun 7: 12819
Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong K-K, Loda M, Weissleder R et al (2015) Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res 21: 396–404
Ali K, Camps M, Pearce WP, Ji H, Rückle T, Kuehn N, Pasquali C, Chabert C, Rommel C, Vanhaesebroeck B (2008) Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 180: 2538–2544
Alix-Panabières C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6: 479–491
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B et al (2019) Alpelisib for PIK3CA -mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380: 1929–1940
Baer R, Cintas C, Dufresne M, Cassant-Sourdy S, Schönhuber N, Planque L, Lulka H, Couderc B, Bousquet C, Garmy-Susini B et al (2014) Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α. Genes Dev 28: 2621–2635
Barlaam B, Cosulich S, Degorce S, Fitzek M, Green S, Hancox U, Lambert-van der Brempt C, Lohmann J-J, Maudet M, Morgentin R et al (2015) Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N, N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers. J Med Chem 58: 943–962
Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P et al (2015) PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 7: 283ra51
Bousquet C, Guillermet-Guibert J, Saint-Laurent N, Archer-Lahlou E, Lopez F, Fanjul M, Ferrand A, Fourmy D, Pichereaux C, Monsarrat B et al (2006) Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO J 25: 3943–3954
Burger MT, Pecchi S, Wagman A, Ni Z-J, Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y, Bartulis S et al (2011) Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med Chem Lett 2: 774–779
Castellano E, Sheridan C, Thin M, Nye E, Spencer-Dene B, Diefenbacher M, Moore C, Kumar M, Murillo M, Grönroos E et al (2013) Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 24: 617–630
Cayron C, Guillermet-Guibert J (2020) The type of KRAS mutation drives PI3Kα/γ signalling dependency: implication for the choice of targeted therapy in pancreatic adenocarcinoma patients. Clin Res Hepatol Gastroenterol 45: 101473
Celià-Terrassa T, Kang Y (2016) Distinctive properties of metastasis-initiating cells. Genes Dev 30: 892–908
Chen Q, Zhang XH-F, Massagué J (2011) Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20: 538–549
Chen Y, LeBleu VS, Carstens JL, Sugimoto H, Zheng X, Malasi S, Saur D, Kalluri R (2018) Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent metastasis program. EMBO Mol Med 10: e9085
Choy CH, Han B-K, Botelho RJ (2017) Phosphoinositide diversity, distribution, and effector function: stepping out of the box. BioEssays 39: 1700121
Cintas C, Douche T, Therville N, Arcucci S, Ramos-Delgado F, Basset C, Thibault B, Guillermet-Guibert J (2018) Signal-targeted therapies and resistance mechanisms in pancreatic cancer: future developments reside in proteomics. Cancers 10: 174
Clark J, Anderson KE, Juvin V, Smith TS, Karpe F, Wakelam MJO, Stephens LR, Hawkins PT (2011) Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nat Methods 8: 267–272
Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L et al (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17: 500–503
Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P (2019) Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 68: 742–758
Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, Barilla R, Torres-Hernandez A, Hundeyin M, Mani VRK et al (2016) γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation. Cell 166: 1485–1499.e15
Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B et al (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368: 1199–1209
Delaloge S, DeForceville L (2017) Targeting PI3K/AKT pathway in triple-negative breast cancer. Lancet Oncol 18: 1293–1294
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985–990
Dougan M, Dranoff G, Dougan SK (2019) GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity 50: 796–811
Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong Bo et al (2013) Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23: 406–420
Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA et al (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51: 5522–5532
Foukas LC, Bilanges B, Bettedi L, Pearce W, Ali K, Sancho S, Withers DJ, Vanhaesebroeck B (2013) Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism. EMBO Mol Med 5: 563–571
Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A et al (2014) Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther 13: 1117–1129
Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319: 195–198
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park J-O, Hochhauser D, Arnold D, Oh D-Y et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381: 317–327
Goncalves MD, Hopkins BD, Cantley LC (2018) Phosphatidylinositol 3-kinase, growth disorders, and cancer. N Engl J Med 379: 2052–2062
Graupera M, Guillermet-Guibert J, Foukas LC, Phng L-K, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR et al (2008) Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453: 662–666
Griesmann H, Drexel C, Milosevic N, Sipos B, Rosendahl J, Gress TM, Michl P (2017) Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Gut 66: 1278–1285
Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, Pradayrol L, Buscail L, Susini C, Bousquet C (2003) Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci USA 100: 155–160
Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469–483
Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, Anderson AO, Waters AM, Diehl JN, Papke B et al (2020) Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer. Cancer Discov 10: 104–123
Höland K, Boller D, Hagel C, Dolski S, Treszl A, Pardo OE, Ćwiek P, Salm F, Leni Z, Shepherd PR et al (2014) Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS One 9: e94132
Hu H, Juvekar A, Lyssiotis C, Lien E, Albeck J, Oh D, Varma G, Hung Y, Ullas S, Lauring J et al (2016) Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton. Cell 164: 433–446
Huang L, Sherchan P, Wang Y, Reis C, Applegate RL, Tang J, Zhang JH (2015) Phosphoinositide 3-kinase gamma contributes to neuroinflammation in a rat model of surgical brain injury. J Neurosci 35: 10390–10401
Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y et al (2005) PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11: 507–514
Jamieson S, Flanagan J, Kolekar S, Buchanan C, Kendall J, Lee W-J, Rewcastle G, Denny W, Singh R, Dickson J et al (2011) A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J 438: 53–62
Junttila MR, Devasthali V, Cheng JH, Castillo J, Metcalfe C, Clermont AC, Otter DD, Chan E, Bou-Reslan H, Cao T et al (2015) Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. Mol Cancer Ther 14: 40–47
Kingham E, Welham M (2009) Distinct roles for isoforms of the catalytic subunit of class-IA PI3K in the regulation of behaviour of murine embryonic stem cells. J Cell Sci 122: 2311–2321
Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB, Coan K, Abraham RT, Shokat KM (2004) Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 12: 4749–4759
Kong Bo, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, Jian Z, Jäger C, Regel I, Raulefs S et al (2016) A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut 65: 647–657
Lamb RF, Ozanne BW, Roy C, McGarry L, Stipp C, Mangeat P, Jay DG (1997) Essential functions of ezrin in maintenance of cell shape and lamellipodial extension in normal and transformed fibroblasts. Curr Biol 7: 682–688
Le Tourneau C, Delord J-P, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani M-A, Mauborgne C et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16: 1324–1334
Lee B, Lipton L, Cohen J, Tie J, Javed Aa, Li L, Goldstein D, Burge M, Cooray P, Nagrial A et al (2019) Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol 30: 1472–1478
Li B, Vincent A, Cates J, Brantley-Sieders DM, Polk DB, Young PP (2009) Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res 69: 338–348
Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, Eberlein C, Lenaghan C, Polanski R, Avivar-Valderas A et al (2018) Combined inhibition of PI3Kβ and mTOR inhibits growth of PTEN-null tumors. Mol Cancer Ther 17: 2309–2319
Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K et al (2018) Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med 10: eaat4921
Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Öllinger R, Zwiebel M, Strong A et al (2018) Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 554: 62–68
Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH (2018) Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol 15: 333–348
Nomura S, Yoshitomi H, Takano S, Shida T, Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A et al (2008) FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br J Cancer 99: 305–313
Padoan A, Plebani M, Basso D (2019) Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci 20: 676
Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight Za, Shokat Km, Azar N, Viguié F et al (2008) PI-103, a dual inhibitor of class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22: 1698–1706
Pietrasz D, Pécuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, Imbert-Bismut F, Karoui M, Vaillant J-C, Taly V et al (2017) Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res 23: 116–123
Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C et al (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem 49: 3857–3871
Pons-Tostivint E, Thibault B, Guillermet-Guibert J (2017) Targeting PI3K signaling in combination cancer therapy. Trends Cancer 3: 454–469
Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, Quertinmont E, Svrcek M, Elarouci N, Iovanna J et al (2018) Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology 155: 1999–2013.e3
Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F et al (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8: 1725–1738
Rhim A, Mirek E, Aiello N, Maitra A, Bailey J, McAllister F, Reichert M, Beatty G, Rustgi A, Vonderheide R et al (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148: 349–361
Roca H, Jones JD, Purica MC, Weidner S, Koh AJ, Kuo R, Wilkinson JE, Wang Y, Daignault-Newton S, Pienta KJ et al (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128: 248–266
Rodon J, Dienstmann R, Serra V, Tabernero J (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10: 143–153
Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89: 457–467
Sastra SA, Olive KP (2013) Quantification of murine pancreatic tumors by high-resolution ultrasound. Methods Mol Biol 980: 249–266
Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ (2003) Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 89: 2110–2115
Schwarzenbach H, Hoon DSB, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426–437
Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, Pandya SS, Scheffold C, Laird AD, Nguyen LT et al (2014) Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 20: 233–245
Sivaram N, McLaughlin PA, Han HV, Petrenko O, Jiang Y-P, Ballou LM, Pham K, Liu C, van der Velden AW, Lin RZ (2019) Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer. J Clin Invest 129: 3264–3276
Therville N, Arcucci S, Vertut A, Ramos-Delgado F, Da Mota DF, Dufresne M, Basset C, Guillermet-Guibert J (2019) Experimental pancreatic cancer develops in soft pancreas: novel leads for an individualized diagnosis by ultrafast elasticity imaging. Theranostics 9: 6369–6379
Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, Molina F (2010) Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 38: 6159–6175
Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15: 7–24
Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D (2008) A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J 415: 97–110
Torres C, Mancinelli G, Cordoba-Chacon J, Viswakarma N, Castellanos K, Grimaldo S, Kumar S, Principe D, Dorman MJ, McKinney R et al (2019) p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity. Proc Natl Acad Sci USA 116: 14724–14733
Tosolini M, Algans C, Pont F, Ycart B, Fournié J-J (2016) Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. Oncoimmunology 5: e1188246
Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC (2005) Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30: 194–204
Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11: 329–341
Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518: 495–501
Witkiewicz AK, McMillan EA, Balaji U, Baek GuemHee, Lin W-C, Mansour J, Mollaee M, Wagner K-U, Koduru P, Yopp A et al (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6: 6744
Wu C-Y, Carpenter ES, Takeuchi KK, Halbrook CJ, Peverley LV, Bien H, Hall JC, DelGiorno KE, Pal D, Song Y et al (2014) PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology 147: 1405–1416.e7
Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A et al (2017) A pan-cancer proteogenomic atlas of PI3K/Akt/mTOR pathway alterations. Cancer Cell 31: 820–832.e3